[Interaction of estrogens and genetic risk factors for thrombosis].
Deep venous thrombosis (DVT) is associated with a genetic risk factor in about half of all cases. Antithrombin, protein C or protein S deficiencies account for 5 to 10 per cent of hereditary thrombophilia whereas the Arg 506 Gln factor V mutation is found in 20 to 30 per cent of DVTs and the G20210A factor II gene mutation in 5 to 10 per cent of them. The risk for DVT is increased three- to fourfold in women using oral contraceptives (OC); it is also increased during menopause hormonotherapy. Oestrogens modify the haemostatic balance, inferring a role in the thrombotic risk. The only thrombophilic factor which in association with OC was demonstrated to multiply the risk is the factor V Arg 506 Gln mutation, with a relative risk around 30. This observation reinforces the hypothesis that venous thrombosis is a multifactorial disease.
Aiach
M
M
Laboratoire d'Hémostase, Hôpital Broussais, Paris, France.
D019943:Amino Acid Substitution; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000502:physiology* / Q000627:therapeutic use; D005165:Factor V / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D012307:Risk Factors; D019851:Thrombophilia / Q000235:genetics; D020246:Venous Thrombosis / Q000453:epidemiology* / Q000235:genetics* / Q000503:physiopathology
D004967:Estrogens; D005165:Factor V